{"doi":"10.1016/j.ijrobp.2023.05.023","title":"A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer","abstract":"PurposeMagnetic resonance (MR) image guidance may facilitate safe ultrahypofractionated radiation dose escalation for inoperable pancreatic ductal adenocarcinoma. We conducted a prospective study evaluating the safety of 5-fraction stereotactic MR-guided on-table adaptive radiation therapy (SMART) for locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC).Methods and MaterialsPatients with LAPC or BRPC were eligible for this multi-institutional, single-arm, phase 2 trial after ≥3 months of systemic therapy without evidence of distant progression. Fifty gray in 5 fractions was prescribed on a 0.35T MR-guided radiation delivery system. The primary endpoint was acute grade ≥3 gastrointestinal (GI) toxicity definitely attributed to SMART.ResultsOne hundred thirty-six patients (LAPC 56.6%, BRPC 43.4%) were enrolled between January 2019 and January 2022. Mean age was 65.7 (36-85) years. Head of pancreas lesions were most common (66.9%). Induction chemotherapy mostly consisted of (modified)FOLFIRINOX (65.4%) or gemcitabine/nab-paclitaxel (16.9%). Mean CA19-9 after induction chemotherapy and before SMART was 71.7 U/mL (0-468). On-table adaptive replanning was performed for 93.1% of all delivered fractions. Median follow-up from diagnosis and SMART was 16.4 and 8.8 months, respectively. The incidence of acute grade ≥3 GI toxicity possibly or probably attributed to SMART was 8.8%, including 2 postoperative deaths that were possibly related to SMART in patients who had surgery. There was no acute grade ≥3 GI toxicity definitely related to SMART. One-year overall survival from SMART was 65.0%.ConclusionsThe primary endpoint of this study was met with no acute grade ≥3 GI toxicity definitely attributed to ablative 5-fraction SMART. Although it is unclear whether SMART contributed to postoperative toxicity, we recommend caution when pursuing surgery, especially with vascular resection after SMART. Additional follow-up is ongoing to evaluate late toxicity, quality of life, and long-term efficacy. Magnetic resonance (MR) image guidance may facilitate safe ultrahypofractionated radiation dose escalation for inoperable pancreatic ductal adenocarcinoma. We conducted a prospective study evaluating the safety of 5-fraction stereotactic MR-guided on-table adaptive radiation therapy (SMART) for locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Patients with LAPC or BRPC were eligible for this multi-institutional, single-arm, phase 2 trial after ≥3 months of systemic therapy without evidence of distant progression. Fifty gray in 5 fractions was prescribed on a 0.35T MR-guided radiation delivery system. The primary endpoint was acute grade ≥3 gastrointestinal (GI) toxicity definitely attributed to SMART. One hundred thirty-six patients (LAPC 56.6%, BRPC 43.4%) were enrolled between January 2019 and January 2022. Mean age was 65.7 (36-85) years. Head of pancreas lesions were most common (66.9%). Induction chemotherapy mostly consisted of (modified)FOLFIRINOX (65.4%) or gemcitabine/nab-paclitaxel (16.9%). Mean CA19-9 after induction chemotherapy and before SMART was 71.7 U/mL (0-468). On-table adaptive replanning was performed for 93.1% of all delivered fractions. Median follow-up from diagnosis and SMART was 16.4 and 8.8 months, respectively. The incidence of acute grade ≥3 GI toxicity possibly or probably attributed to SMART was 8.8%, including 2 postoperative deaths that were possibly related to SMART in patients who had surgery. There was no acute grade ≥3 GI toxicity definitely related to SMART. One-year overall survival from SMART was 65.0%. The primary endpoint of this study was met with no acute grade ≥3 GI toxicity definitely attributed to ablative 5-fraction SMART. Although it is unclear whether SMART contributed to postoperative toxicity, we recommend caution when pursuing surgery, especially with vascular resection after SMART. Additional follow-up is ongoing to evaluate late toxicity, quality of","journal":"International Journal of Radiation Oncology*Biology*Physics","year":2023,"id":315961,"datarank":2.3658356557556246,"base_score":4.820281565605037,"endowment":4.820281565605037,"self_citation_contribution":0.7230422348407557,"citation_network_contribution":1.6427934209148687,"self_endowment_contribution":0.7230422348407557,"citer_contribution":1.6427934209148687,"corpus_percentile":null,"corpus_rank":null,"citation_count":123,"citer_count":85,"citers_with_citation_signal":41,"citers_with_endowment":41,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9554,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03621644"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":234976,"name":"Percy Lee","orcid":"0000-0001-6004-840X","position":1,"is_corresponding":false},{"id":534984,"name":"Daniel A. Low","orcid":"0000-0002-6425-9228","position":2,"is_corresponding":false},{"id":696680,"name":"Joshua Kim","orcid":"0000-0001-8371-2852","position":3,"is_corresponding":false},{"id":1018443,"name":"Kathryn E. Mittauer","orcid":"0000-0002-6213-611X","position":4,"is_corresponding":false},{"id":601008,"name":"M. Bassetti","orcid":"0000-0001-5012-8596","position":5,"is_corresponding":false},{"id":234975,"name":"Carri Glide‐Hurst","orcid":"0000-0001-7989-4382","position":6,"is_corresponding":false},{"id":881229,"name":"Ann C. Raldow","orcid":"0000-0001-8996-6810","position":7,"is_corresponding":false},{"id":935967,"name":"Yingli Yang","orcid":"0000-0002-6472-5567","position":8,"is_corresponding":false},{"id":258164,"name":"Lorraine Portelance","orcid":"0000-0003-2806-2951","position":9,"is_corresponding":false},{"id":1018444,"name":"Kyle R. Padgett","orcid":"0000-0002-6277-5317","position":10,"is_corresponding":false},{"id":310167,"name":"Bassem I. Zaki","orcid":null,"position":11,"is_corresponding":false},{"id":250013,"name":"Rongxiao Zhang","orcid":"0000-0002-0423-7828","position":12,"is_corresponding":false},{"id":407153,"name":"Hyun Kim","orcid":"0000-0003-4029-8764","position":13,"is_corresponding":false},{"id":917508,"name":"Lauren E. Henke","orcid":"0000-0003-2208-3241","position":14,"is_corresponding":false},{"id":950468,"name":"Alex Price","orcid":"0000-0002-9054-6474","position":15,"is_corresponding":false},{"id":237057,"name":"Joseph D. Mancias","orcid":"0000-0002-0692-3717","position":16,"is_corresponding":false},{"id":806861,"name":"Christopher L. Williams","orcid":"0000-0002-9966-5568","position":17,"is_corresponding":false},{"id":1018445,"name":"John Ng","orcid":"0000-0002-2840-0239","position":18,"is_corresponding":false},{"id":1019206,"name":"Ryan Pennell","orcid":null,"position":19,"is_corresponding":false},{"id":1019207,"name":"M. Raphael Pfeffer","orcid":null,"position":20,"is_corresponding":false},{"id":1019208,"name":"Daphne Levin","orcid":null,"position":21,"is_corresponding":false},{"id":10971,"name":"Adam C. Mueller","orcid":"0000-0003-2678-0159","position":22,"is_corresponding":false},{"id":1018446,"name":"Karen Mooney","orcid":"0009-0005-4612-6906","position":23,"is_corresponding":false},{"id":1018447,"name":"Patrick Kelly","orcid":"0000-0003-4098-2734","position":24,"is_corresponding":false},{"id":1018448,"name":"Amish P. Shah","orcid":"0009-0006-1887-9297","position":25,"is_corresponding":false},{"id":103878,"name":"Luca Boldrini","orcid":"0000-0002-5631-1575","position":26,"is_corresponding":false},{"id":1018449,"name":"Lorenzo Placidi","orcid":"0000-0003-0058-9145","position":27,"is_corresponding":false},{"id":1019209,"name":"Martin Fuß","orcid":null,"position":28,"is_corresponding":false},{"id":259432,"name":"Michael D. Chuong","orcid":"0000-0001-8328-7518","position":29,"is_corresponding":false},{"id":171733,"name":"Parag J. Parikh","orcid":null,"position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-19T01:06:32.274501Z","pmid":"37210048","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}